Future Medicines

Future Medicines is a South Korean clinical-stage biotechnology company specializing in the development of first-in-class small molecule therapeutics. The company leverages its proprietary nucleoside-based drug discovery platform to target adenosine receptors and other key biological pathways involved in metabolic and inflammatory diseases. Its lead candidate, FM101, is a highly selective A3 adenosine receptor antagonist currently being evaluated in Phase 2 clinical trials for Non-alcoholic steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC). Beyond liver diseases, the company's pipeline extends into oncology, ophthalmology, and metabolic disorders such as obesity. Future Medicines aims to address significant unmet medical needs through innovative medicinal chemistry and strategic global clinical development.